IRIS
RUMI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.262
AS - Asia 5.154
EU - Europa 3.624
SA - Sud America 803
AF - Africa 178
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 13
Totale 16.050
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.080
CN - Cina 2.167
SG - Singapore 1.143
IE - Irlanda 873
HK - Hong Kong 674
BR - Brasile 622
VN - Vietnam 571
RU - Federazione Russa 450
DE - Germania 396
FI - Finlandia 391
IT - Italia 342
FR - Francia 308
UA - Ucraina 290
GB - Regno Unito 160
SE - Svezia 152
IN - India 110
BD - Bangladesh 98
CA - Canada 86
ZA - Sudafrica 68
AR - Argentina 65
MX - Messico 65
IQ - Iraq 45
AT - Austria 44
NL - Olanda 43
PK - Pakistan 43
TR - Turchia 39
PL - Polonia 38
JP - Giappone 34
ID - Indonesia 31
CO - Colombia 29
RO - Romania 28
MA - Marocco 27
MY - Malesia 26
ES - Italia 22
SA - Arabia Saudita 22
VE - Venezuela 21
EC - Ecuador 20
UZ - Uzbekistan 18
CL - Cile 16
JO - Giordania 16
PY - Paraguay 16
EG - Egitto 15
PH - Filippine 15
AU - Australia 14
BE - Belgio 14
KE - Kenya 14
AE - Emirati Arabi Uniti 13
LT - Lituania 11
CZ - Repubblica Ceca 10
NP - Nepal 10
AZ - Azerbaigian 9
TN - Tunisia 9
IL - Israele 8
KZ - Kazakistan 8
DZ - Algeria 7
EU - Europa 7
JM - Giamaica 7
LB - Libano 7
MU - Mauritius 7
CH - Svizzera 6
OM - Oman 6
UY - Uruguay 6
ET - Etiopia 5
KG - Kirghizistan 5
KR - Corea 5
LA - Repubblica Popolare Democratica del Laos 5
LV - Lettonia 5
PT - Portogallo 5
RS - Serbia 5
AL - Albania 4
CR - Costa Rica 4
GR - Grecia 4
LK - Sri Lanka 4
NG - Nigeria 4
NI - Nicaragua 4
PA - Panama 4
PE - Perù 4
QA - Qatar 4
TH - Thailandia 4
XK - ???statistics.table.value.countryCode.XK??? 4
AM - Armenia 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
HN - Honduras 3
MD - Moldavia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CG - Congo 2
DK - Danimarca 2
GA - Gabon 2
GD - Grenada 2
HU - Ungheria 2
KH - Cambogia 2
LY - Libia 2
MK - Macedonia 2
Totale 16.019
Salva come PNG Salva come JPEG
Città #
Dublin 872
San Jose 679
Hong Kong 660
Chandler 643
Ashburn 622
Singapore 552
Dallas 533
Jacksonville 426
Nanjing 394
Beijing 383
Boardman 262
Lauterbourg 242
Ho Chi Minh City 194
Los Angeles 173
Princeton 167
Nanchang 164
Lawrence 158
New York 158
Helsinki 138
Hanoi 123
Wilmington 121
Shenyang 118
Changsha 116
Hebei 110
Medford 101
Council Bluffs 97
Munich 97
Jiaxing 91
Shanghai 84
Buffalo 80
Ann Arbor 79
Tianjin 77
Moscow 69
Redondo Beach 63
Hangzhou 62
Santa Clara 56
São Paulo 55
Johannesburg 53
Milan 47
Orem 42
Pavia 41
Nuremberg 39
Toronto 36
Da Nang 34
Seattle 34
Turku 34
Rome 32
Frankfurt am Main 30
Tokyo 30
Brooklyn 29
Haiphong 29
Warsaw 29
Woodbridge 29
Denver 28
Norwalk 28
Chennai 25
Falkenstein 24
Mexico City 24
Montreal 23
San Francisco 22
Stockholm 22
Timisoara 22
The Dalles 21
Washington 21
Chicago 20
Vienna 20
Boston 19
Guangzhou 18
Houston 18
Rio de Janeiro 18
London 17
Atlanta 15
Baghdad 15
Fairfield 15
Hải Dương 15
Manchester 15
Tashkent 15
Amman 14
Brussels 14
Jinan 14
Poplar 14
Verona 14
Zhengzhou 14
Florence 13
Rawalpindi 13
Buenos Aires 12
Curitiba 12
Ankara 11
Columbus 11
Auburn Hills 10
Belo Horizonte 10
Catania 10
Kuala Lumpur 10
Lahore 10
Phoenix 10
Amsterdam 9
Biên Hòa 9
Bogotá 9
Campinas 9
Charlotte 9
Totale 10.328
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 188
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 179
An insidious presentation of splenic marginal zone lymphoma 158
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 154
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 147
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 146
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 145
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 144
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 144
Blast phase of essential thrombocythemia: A single center study. 138
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 137
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 135
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 132
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 130
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 128
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 128
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 126
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 125
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 122
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 119
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 118
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 117
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 117
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 117
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 117
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 115
Clinical significance of somatic mutation in unexplained blood cytopenia 115
Acute arterial and deep venous thromboembolism in COVID-19 patients: Risk factors and personalized therapy 113
Diagnosis and management of prefibrotic myelofibrosis. 111
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 110
JAK2 (V617F) mutation in healthy individuals 109
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 107
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 107
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 107
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 106
Allelic imbalance in CALR somatic mutagenesis 106
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 106
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 105
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 104
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 104
A journey through infectious risk associated with ruxolitinib. 104
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 102
Somatic mutations of calreticulin in myeloproliferative neoplasms 102
Facing erythrocytosis: Results of an international physician survey. 102
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 100
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 100
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 99
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 99
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 99
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 99
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 98
Role of the molecular staging and response in the management of follicular lymphoma patients 97
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 97
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 97
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 97
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 96
Clinical relevance of JAK2 (V617F) mutant allele burden 96
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. 96
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 94
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 94
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 93
Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). 93
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 93
Peripheral intraneutrophil diplococci in a case of meningococcemia. 92
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. 92
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 92
Familial chronic myeloproliferative disorders: the state of the art 91
Cardiovascular events and intensity of treatment in polycythemia vera. 91
Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver 90
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 90
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms 89
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 89
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 89
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 89
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. 89
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 89
COVID-19 in Patients with Hematologic Diseases 88
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 88
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 87
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 87
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 87
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 87
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 85
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 85
Mutations and prognosis in primary myelofibrosis 85
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 85
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 85
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms 84
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 84
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib 84
Improving survival trends in primary myelofibrosis: an international study. 84
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 83
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 82
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 82
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 81
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. 81
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 81
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. 80
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms 80
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 80
Totale 10.470
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.773
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.773
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202118 0 0 0 0 0 0 0 0 0 0 0 18
2021/2022692 9 4 23 11 17 38 6 38 33 38 115 360
2022/20232.087 222 118 21 135 204 169 1 100 989 13 87 28
2023/20241.049 119 170 55 69 96 297 27 66 10 22 76 42
2024/20252.759 66 208 72 61 56 120 198 204 641 114 370 649
2025/20266.707 497 556 786 788 723 311 1.281 239 587 518 250 171
Totale 16.448